In the Alzheimer’s disease brain, the amyloid beta peptide clumps together to form hardened plaques between nerve cells.
Key Takeaways
- Researchers have developed a method based on artificial intelligence that rapidly identifies currently available medications that may treat Alzheimer’s disease.
- The method also reveals potential new treatment targets for the disease.
Independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies.
Mark Albers, MD, PhD
Associate Director, Massachusetts Center for Alzheimer Therapeutic Science, Massachusetts General Hospital
New treatments for Alzheimer’s disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. Now a team at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has developed an artificial intelligence–based method to screen currently available medications as possible treatments for Alzheimer’s disease. The method could represent a rapid and inexpensive way to repurpose existing therapies into new treatments for this progressive, debilitating neurodegenerative condition. Importantly, it could also help reveal new, unexplored targets for therapy by pointing to mechanisms of drug action.
“Repurposing FDA-approved drugs for Alzheimer’s disease is an attractive idea that can help accelerate the arrival of effective treatment—but unfortunately, even for previously approved drugs, clinical trials require substantial resources, making it impossible to evaluate every drug in patients with Alzheimer’s disease,” explains Artem Sokolov, PhD, director of Informatics and Modeling at the Laboratory of Systems Pharmacology at HMS. “We therefore built a framework for prioritizing drugs, helping clinical studies to focus on the most promising ones.”
In an article published in Nature Communications, Sokolov and his colleagues describe their framework, called DRIAD (Drug Repurposing In Alzheimer’s Disease), which relies on machine learning—a branch of artificial intelligence in which systems are “trained” on vast amounts of data, “learn” to identify telltale patterns and augment researchers’ and clinicians’ decision-making.
DRIAD works by measuring what happens to human brain neural cells when treated with a drug. The method then determines whether the changes induced by a drug correlate with molecular markers of disease severity.
The approach also allowed the researchers to identify drugs that had protective as well as damaging effects on brain cells.
“We also approximate the directionality of such correlations, helping to identify and filter out neurotoxic drugs that accelerate neuronal death instead of preventing it,” says co-first author Steve Rodriguez, PhD, an investigator in the Department of Neurology at MGH and an instructor at HMS.
DRIAD also allows researchers to examine which proteins are targeted by the most promising drugs and if there are common trends among the targets, an approach designed by Clemens Hug, PhD, a research associate in the Laboratory of Systems Pharmacology and a co-first author.
The team applied the screening method to 80 FDA-approved and clinically tested drugs for a wide range of conditions. The analysis yielded a ranked list of candidates, with several anti-inflammatory drugs used to treat rheumatoid arthritis and blood cancers emerging as top contenders. These drugs belong to a class of medications known as Janus kinase inhibitors. The drugs work by blocking the action of inflammation-fueling Janus kinase proteins, suspected to play a role in Alzheimer’s disease and known for their role in autoimmune conditions. The team’s analyses also pointed to other potential treatment targets for further investigation.
“We are excited to share these results with the academic and pharmaceutical research communities. Our hope is that further validation by other researchers will refine the prioritization of these drugs for clinical investigation,” says Mark Albers, MD, PhD, the Frank Wilkins Jr. and Family Endowed Scholar and associate director of the Massachusetts Center for Alzheimer Therapeutic Science at MGH and a faculty member of the Laboratory of Systems Pharmacology at HMS. One of these drugs, baricitinib, will be investigated by Albers in a clinical trial for patients with subjective cognitive complaints, mild cognitive impairment, and Alzheimer’s disease that will be launching soon at MGH in Boston and at Holy Cross Health in Fort Lauderdale, Florida. “In addition, independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies,” says Albers.
Original Article: Artificial intelligence reveals current drugs that may help combat Alzheimer’s disease
More from: Massachusetts General Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Artificial intelligence to identify new drug treatments
- AI model mimics randomized clinical trials for determining optimal stroke prevention treatment
Scientists have designed a new artificial intelligence model that emulates ... "Our model could be an acceleratory module that could help first identify a small group of candidate drugs that are ...
- With huge patient dataset, AI accurately predicts treatment outcomes
Scientists have designed a new artificial intelligence model that emulates randomized clinical trials to determine the treatment options most effective at preventing stroke in people with heart ...
- Every Cure and BioPhy launch partnership on drug repurposing
Every Cure is a non-profit that looks to identify ... drugs, BioPhy seeks to unlock potential uses for emerging drugs," Grant Mitchell, MD, MBA, co-founder and CEO of Every Cure, told VatorNews. "The ...
- Every Cure Deploys BioPhy’s Artificial Intelligence Platform to Accelerate its Mission of Repurposing Drugs for Untreated Diseases
BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every ...
- Mental-health professionals explore AI-powered digital therapeutics to treat patients and improve care
There's a shortage of mental-health providers. AI is being used to bridge the gap by helping analyze symptoms and offering patients treatment plans.
Go deeper with Google Headlines on:
Artificial intelligence to identify new drug treatments
[google_news title=”” keyword=”artificial intelligence to identify new drug treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
New Alzheimer’s treatment targets
- Scientists reveal nanoparticle that can treat Alzheimer’s disease in mice
Researchers say a promising new therapy targets protein clusters that likely cause neuron death and brain atrophy in Alzheimer’s disease.
- New Study Finds Link Between High-Fat Diet, Increased Risk of Alzheimer’s
The results of this study are a step forward in our understanding of this disease and may explain the relationship between obesity, Type 2 diabetes, ...
- Dementia News
Mar. 26, 2024 — Researchers have identified a new potential target for the treatment of Alzheimer's disease -- PDE4B. The researchers observed that AD mice showed memory deficits in maze tests ...
- Alzheimer's News
New Treatment Target Identified for Alzheimer's Disease Mar. 26, 2024 — Researchers have identified a new potential target for the treatment of Alzheimer's disease -- PDE4B. The researchers ...
- Researchers discover the mechanism that links a diet rich in fats with Alzheimer's disease
A study led by the Universitat Rovira i Virgili (URV) has revealed the mechanism behind the link between a diet high in saturated fats and Alzheimer's disease. The research focused on how this kind of ...
Go deeper with Google Headlines on:
New Alzheimer’s treatment targets
[google_news title=”” keyword=”new Alzheimer’s treatment targets” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
[embedyt] https://www.youtube.com/embed?listType=playlist&list=PL0UjJ07OSXC83oV409r1yRju8-ihA1InJ&layout=gallery[/embedyt]